CDK4/CDK6 inhibitors are widely used with endocrine therapy (ET) for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer to overcome ET resistance and improve the outcomes of the patients.1,2 In this exclusive video, Dr. E. Ciruelos discusses a clinical case of early recurrence of HR+/HER2- breast cancer with visceral disease. In addition, she also shares how abemaciclib, combined with fulvestrant, reduces the tumor size, increases overall survival and progression-free survival in HR+/HER2- breast cancer patients with visceral disease.
References 1. Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine…